Meric-Bernstam, MD, Discusses Pertuzumab Plus Trastuzumab Use Across HER2-Positive Solid Tumors

News
Video

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Funda Meric-Bernstam, MD, of The University of Texas MD Anderson Cancer Center, about using pertuzumab (Perjeta) plus trastuzumab (Herceptin) to help treat advanced solid tumors with HER2 overexpression or amplification. The MyPathway study (NCT02091141) from which the data were derived is a basket trial assessing already approved oncologic drugs across a range of tissue-agnostic indication.

The portion of the study examined showed that using pertuzumab plus trastuzumab was active in KRAS wild-type, HER2 amplified or overexpressed tumors. However, the study found limited activity in KRAS-mutated tumors.

Transcript:

This study suggests that this is a time where we really need to be thoughtful about looking at molecular reports. I do think the data on activity is strong enough for HER2 testing and should be considered for patients broadly, especially for patients that are already undergoing germline testing. [With] HER2 amplification in the absence of KRAS mutation, we should consider HER2-targeted therapies. I do want to point out that KRASmutations conferring resistance [are] not just limited to pertuzumab and trastuzumab and are probably relevant to other combinations of monoclonal antibodies and small molecule inhibitors, as well. We would potentially be reluctant to extrapolate other novel technologies targeting HER2 now. I think HER2 is a driver across tumor types that only needs to be pursued when it is visualized.

References

Meric-Bernstam F, Hainsworth J, Bose R, et al. MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. J Clin Oncol. 2021;39(suppl 15):3004. doi: 10.1200/JCO.2021.39.15_suppl.3004

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content